Yekaterina Chudnovsky
Yekaterina Chudnovsky's purchase track record
Yekaterina Chudnovsky has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/22/2023 | ELTX | $7.05M | +5.7% | +3.6% | +14.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ELTX presents Phase 2 data at ESMO Congress; B. Riley lowers target. Elicio Therapeutics disclosed that its late‑breaking Phase 2 AMPLIFY‑7P results have been selected for an oral presentation at the upcoming ESMO Congress 2026. The selection highlights ongoing clinical progress for the company's oncology program. Separately, B. Riley Securities kept its coverage on ELTX but reduced its price target to $8, reflecting a more cautious outlook.
Transaction History
| IMMX | ▲ Buy | Grant | 6,250 | $0 | 5/22/2026 | View on chart |
| ELTX | ▼ Sell | Other | 3,500,573 | $20.3M | 3/5/2025 | View on chart |
| ELTX | ▲ Buy | Open Market | 1,213,000 | $7.0M | 12/22/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
IMMX Holds Shareholder and Analyst Call
Immix Biopharma hosted a shareholder and analyst conference call, sharing recent company updates and answering questions. The discussion gave participants insight into the company's current activities and outlook. Such calls can influence how investors view the business and its progress.
IMMX Holds Shareholder and Analyst Call. Immix Biopharma hosted a shareholder and analyst conference call, sharing recent company updates and answering questions. The discussion gave participants insight into the company's current activities and outlook. Such calls can influence how investors view the business and its progress.